Insmed (INSM) Misses Q4 EPS by 17c; Offers FY23 ARIKAYCE Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 23, 2023 7:30 AM ESTPatient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024
Company to Share Robust Updates Across Early-Stage Programs at Research Day on May 8, 2023
Company on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE® (amikacin liposome inhalation suspension) in Third Quarter of 2023
ARIKAYCE Total Revenue of $59.3 Million for the Fourth Quarter and $245.4Â Million for the Full Year 2022, Reflecting 30% Annual Growth
BRIDGEWATER,... More
